Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology firm located in San Diego, California, is dedicated to developing innovative medical treatments for cancer patients. Its lead therapeutic agent is onvansertib, an oral and selective inhibitor of Polo-like Kinase 1 (PLK1), which is being investigated for various anti-cancer applications, including clinical trials for metastatic colorectal cancer. The company's pipeline further includes CY140, an inhibitor targeting PLK1, PLK2, and PLK3, currently progressing through Phase 1/2 studies for both solid tumors and leukemias. Additionally, Cardiff Oncology is advancing TROV-054 in Phase 1b/2 trials, exploring its combination with FOLFIRI and bevacizumab, and TROV-053 in a Phase II clinical trial, where it is being assessed alongside Zytiga for metastatic castration-resistant prostate cancer. Established in 1999, the company, which primarily supplies its pharmaceutical innovations to manufacturers, was originally known as Trovagene, Inc. It officially rebranded to Cardiff Oncology, Inc. in May 2012.